Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
mTOR Inhibition for Cancer Therapy: Past, Present and Future
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
Penetrating Insights
None
Handbook of Anticancer Drug Development
Perhaps no area of pharmacology has progressed further or faster than that of anticancer drugs. With this concise and informative resource, you'll explore the full spectrum of anticancer drug evolution -- from research and development, through clinical trials, to licensure and utilization.
Patlitaxel in Cancer Treatment
This breakthrough reference-the only book of its kind on the subject-provides in-depth coverage of paclitaxel, one of the most broadly active compounds available to treat human malignancy.
Camptothecins in Cancer Therapy
A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.
Principles and Practice of Gynecologic Oncology
This updated Fourth Edition provides comprehensive coverage of the biology of gynecologic cancer, the therapeutic modalities available, and the diagnosis and treatment of site-specific malignancies. Because of the importance of multimodality treatment, the site-specific chapters are co-authored by a surgical oncologist, a medical oncologist, a radiation oncologist, and a pathologist. A significant portion of this edition focuses on monoclonal antibodies, vaccines, and gene directed therapies and how they can greatly improve treatment outcomes. A new chapter on end-of-life care is also included. Three distinguished new editors—Richard R. Barakat, MD, Maurie Markman, MD, and Marcus E. Randall, MD—now join the editorial team.
Principles and Practice of Gynecologic Oncology
Providing comprehensive coverage of the biology of gynecologic cancer, the therapeutic modalities available, and the diagnosis and treatment of site-specific malignancies, this edition has 30 percent new contributing authors and new material. A companion Web site offers a fully searchable text.
Integrated Cancer Management
This definitive, up-to-the-minute reference explores the range of metabolic, nutritional, immunologic, and psychological changes that can occur while treating local, regional, and distant cancer, and examines the influence of these factors on outcomes and recovery. Includes clearly written, concise summaries of oncological therapy emphasizing c
